BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gonzalez J, Andrade DC, Niu J. Cost-consequence analysis of single-dose dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections in a multi-site healthcare system. Clin Infect Dis 2020:ciaa1732. [PMID: 33211794 DOI: 10.1093/cid/ciaa1732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Bassetti M, Labate L, Vena A, Giacobbe DR. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications. Curr Opin Infect Dis 2021;34:96-108. [PMID: 33405480 DOI: 10.1097/QCO.0000000000000714] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Eckmann C, Tulkens PM. Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics. J Antimicrob Chemother 2021;76:iv9-iv22. [PMID: 34849999 DOI: 10.1093/jac/dkab351] [Reference Citation Analysis]
3 Buzón-Martín L, Zollner-Schwetz I, Tobudic S, Cercenado E, Lora-Tamayo J. Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review. Antibiotics (Basel) 2021;10:656. [PMID: 34072670 DOI: 10.3390/antibiotics10060656] [Cited by in F6Publishing: 1] [Reference Citation Analysis]